FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare
Related Topics >> Biotech Venture Capital | Sangart

Sangart - Top 20 VC deals of 2007

January 28, 2008 — 10:42am ET | By Maureen Martino
Tools

Company: Sangart
Based: San Diego, CA
Raised: $50M
Round: Sixth
Investors: Undisclosed Corporate Investor

Scoop: Sangart is currently conducting Phase III trials of its lead product candidate, Hemospan, a hemoglobin-based oxygen carrier designed to serve as an alternative to blood transfusions. The trials are designed to gauge the ability of Hemospan to prevent and treat hemodynamic instability, especially hypotension, or low blood pressure, during orthopedic surgery and will include more than 800 patients.

More News:
Sangart garners $50M in VC. Report

Previous: MicrobiaIndexNext: Ambit Biosciences

SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:
Be the first to comment
More stories about Biotech Venture Capital   Sangart  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.